Darifenacin
CAS 133099-04-4
In Stock
Darifenacin
Cat. No. ANT-DRF-000CAS 133099-04-4In Stock
Technical Data
Cat. No.ANT-DRF-000
CAS133099-04-4
Mol. FormulaC28H30N2O2
Mol. Weight426.55 g/mol
IUPAC2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
SMILESC1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
InChIInChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
InChI KeyHXGBXQDTNZMWGS-RUZDIDTESA-N
Purity99%
Description
Overview
Darifenacin is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010, the US rights were sold to Warner Chilcott for US$400 million
Anant Labs manufacture and furnish high quality Darifenacin impurities for global markets. Our Darifenacin EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
Synonyms
(3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-alpha-alpha-diphenyl-3-pyrrolidineacetamideHydrobromideDarifenacin133099-04-42-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamideUK-88525darifenacineDarifenacinaDarifenacin extended releaseAPG9819VLMUK88525
